Cardiogenic Shock

Cardiogenic Shock

Cardiogenic shock remains a leading cause of death in AMI. The incidence occurs in about 5 - 8% of patients hospitalized with STEMI and has a mortality rate of about 50%. The strategy to stabilize with IABP, treat with reperfusion, and transfer for complete revascularization has thus far yielded the best outcomes and every effort should be made to implement this strategy.1

Current ACC/AHA Guidelines stress the importance stabilizing patients in cardiogenic shock with IABP therapy prior to PCI. It is important to note that patients receiving IABP therapy may be excluded from the Doot-to-Balloon (D2B) time quality measurement metric.

IABP in Cardiogenic Shock:

  • Improves in-hospital and long-term (10yr) survival2
  • Reduces the in-hospital incidence of MACCE3
  • Facilitates patient transport to a tertiary care center1
  • Is a Class I recommendation in the ACC/AHA Guidelines

Improved outcomes and low complication rates

Improved outcomes and low complication rates

IABP therapy, a ACC/AHA Class I indication for the management of cardiogenic shock complicating AMI.

LV unloading with IABC during cardiogenic shock and prior to PCI, significantly reduces in-hospital mortality compared to IABC after revascularization. 4

1 Cardiogenic shock current concepts and improving outcomes. H R Reynolds et al. Circulation 2008 ;117 :686-697

2 Usefulness of IABP counterpulsation in patients with cardiogenic shock from AMI. J M Cheng et al. Am J Cardiol 2009;104:327-332

3 A Prospective Feasibility Trial Investigating the Impella 2.5 System in Patients Undergoing High-Risk PCI. S R Dixon JACC 2009;2:91-6

4 M Abdel-Wahab, et al. Am J Cardiol 2010;105:967-971

Cardiogenic Shock

Interventional Cardiology

Surgery

Resources

Percutaneous Cardiac Assist Devices

Related Links

Contact Us